Analyzing AquaBounty Technologies (NASDAQ:AQB) & Tyra Biosciences (NASDAQ:TYRA)

AquaBounty Technologies (NASDAQ:AQB) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for AquaBounty Technologies and Tyra Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AquaBounty Technologies	1	0	0	0	1.00
Tyra Biosciences	1	0	5	1	2.86

Tyra Biosciences has a consensus target price of $33.17, indicating a potential upside of 27.37%. Given Tyra Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Tyra Biosciences is more favorable than AquaBounty Technologies.

Insider & Institutional Ownership

8.9% of AquaBounty Technologies shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 2.2% of AquaBounty Technologies shares are held by insiders. Comparatively, 15.2% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares AquaBounty Technologies and Tyra Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AquaBounty Technologies	N/A	-553.11%	-283.83%
Tyra Biosciences	N/A	-35.76%	-33.58%

Earnings & Valuation

This table compares AquaBounty Technologies and Tyra Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AquaBounty Technologies	N/A	N/A	-$149.19 million	($0.83)	-1.03
Tyra Biosciences	N/A	N/A	-$86.48 million	($1.87)	-13.93

Tyra Biosciences is trading at a lower price-to-earnings ratio than AquaBounty Technologies, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

AquaBounty Technologies has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Summary

Tyra Biosciences beats AquaBounty Technologies on 9 of the 12 factors compared between the two stocks.

About AquaBounty Technologies

AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.

About Tyra Biosciences

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.